Celltrion Pushes ‘Biobetters’ Concept With Remsima SC
Subcutaneous Biosimilar Infliximab Delivers On The Promise Of Biobetters
Celltrion says its subcutaneous formulation of infliximab makes the biosimilar better than the Remicade original • Source: Shutterstock 
